A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer

British Journal of Cancer

Volumn 75, Issue 2, 1997, Pages 287-294

  Siddiqui, N ^a   Boddy, A V ^b,c   Thomas, H D ^b   Bailey, N P ^a,b   Robson, L ^a   Lind, M J ^a,b   Calvert, A H ^a,b  

^a NEWCASTLE GENERAL HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Carboplatin; Ovarian cancer; Paclitaxel; Phase I

Indexed keywords

ANTINEOPLASTIC AGENT; ANTINEOPLASTIC METAL COMPLEX; CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ALOPECIA; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG TOLERABILITY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MYALGIA; NEUTROPENIA; OVARY CANCER; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0031014464     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1997.47     Document Type: Article

References (45)

1. Adams M, Kerby I J, Rocker I, Evans A, Johansen K and Franks C R (1989) A comparison of the toxicity and efficacy of cisplatin and carboplatin in advanced ovarian cancer. Acta Oncologica 28: 57-60
2. Advanced Ovarian Cancer Trial Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 303: 884-893
3. Al-Azraqi, A, Chapman C, Challen C, Aswad S, Sinha D, Calvert A and Lunec J (1995) P53 mutations in primary human ovarian cancer as a determinant of resistance to carboplatin. Proc Am Assoc Cancer Res 36: 228
4. Alberts D S, Green S, Hannigan E V, O'Toole R, Stock-Novack D, Anderson P, Surwit E A, Malvya V K, Nahhas W A and Jolles CJ (1992) Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a Phase III randomised trial in Stages III and IV ovarian cancer. J Clin Oncol 10: 706-717
5. Belani C P, Aisner J, Hiponia D and Engstrom C (1995) Paclitaxel and carboplatin with and without Filgastrim support in patients with metastatic non-small cell lung cancer. Semin Oncol 22 (suppl.9): 7-12
6. Bolis G, Scarfone G, Maggi R, Melpignanao M, Parazzini F, Presti M, Zanaboni F, Villa A and Gentile A (1995) A dose finding study with fixed dose of carboplatin and escalating paclitaxel (PTX) in advanced ovarian cancer. Proc Am Soc Clin Oncol 14: 270
7. Bookman M A, McGuire W P, Kilpatrick E, Keenan E, Johnson S, O'Dwyer P, Rowinskky E and Ozols, R F (1995) Phase I gynecologic-oncology group (GOG) study of 3-H and 24-H paclitaxel with carboplatin as initial therapy for advanced epithelial ovarian cancer (OvCa). Proc Am Soc Clin Oncol 14: 271
8. Bruckner H W, Cagnoni P J, Lee J-M, Chesser M R and Andreotti P E (1994) A sequence of adriamycin and taxol infusions for refractory ovarian cancer. Proc Am Soc Clin Oncol 13: 276 (890)
9. Bunn P A and Kelly K A (1995) A Phase I study of carboplatin and paclitaxel in non-small cell lung cancer: a University of Colorado Cancer Center study. Semin Oncol 22 (suppl. 9): 2-6
10. Caldas C and Mcguire W P (1993) Paclitaxel (Taxol) therapy in ovarian carcinoma. Semin Oncol 20: 50-55
11. Calvert A H (1994) Dose optimisation of carboplatin in adults. Anticancer Res 14: 2273-2278
12. Calvert A H, Newell D R, Gumbrell L A, O'Reilly S, Burnell M, Boxall F E, Siddik Z H, Judson I R, Gore M E and Wiltshaw E (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756
13. Carboni J M, Singh C and Tepper M A (1993) Taxol and lipopolysaccharide activation of a macrophage cell line induction of similar tyrosine phosphoproteins. J Nat Cancer Inst Monogr. 15: 95-101
14. Cavaletti G, Buglilun G, Marzorat L, Zincone A, Marzola M, Colombo N and Tredici G (1995) Peripheral neurotoxicity of taxol in patients previously treated with cisplatin. Cancer 75: 1141-1150
15. Crook M and Crawford N (1989) Electrokinetic, analytical and functional heterogeneity of circulating human platelets: separation of subpopulations by continuous flow electrophoresis after taxol stabilization. Biochim Biophy Acta - Mol Cell Res 1014: 26-39
16. D'Argenio D Z and Schumitsky A (1990) Adapt II. Interactive Mathematical Software for Pharmacokinetic/Pharmacodynamic Systems Analysis. Biomedical Resources, University of Southern California: Los Angeles.
17. Einzig A I, Wiernik P H, Sasloff J, Runowizc C D and Goldberg G L (1992) Phase II study and long term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. J Clin Oncol 10: 1748-1753
18. Eisenhauer E A, ten Bokkel Huinik W W, Swenerton K D, Gianni L, Myles J, van der Burg MEL, Kerr I, Bermorken J B, Buser K, Colombo N, Bacon M, Santabarbara P, Onetto N, Winograd B and Canetta R (1994) European-Candian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. J Clin Oncol 12: 2654-2666
19. Ghazal-Aswad S, Calvert A H and Newell D R (1996) A single sample assay for the calculation of the area under the free carboplatin plasma concentration versus time curve. Cancer Chemother Pharmacol 37: 429-434
20. Gianni L, Kearns C, Giani A, Capri G, Vigano L, Locatelli A, Bonadonna G and Egorin M (1995) Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13: 180-190
21. Gibaldi M and Perrier D (1982) Pharmacokinetics, Vol. 15. Marcel Dekker: New York.
22. Harland S J, Newell D R, Siddik Z H, Chadwick R, Calvert A H and Harrap K R (1984) Pharmacokinetics of cis-diammine-1, 1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 44: 1693-1697
23. Harvilesky L J, Elbendary A, Hurteua J A, Whitaker R S, Rodriguez G C and Berchuck A (1995) Chemotherapy-induced apoptosis in epithelial ovarian cancers. Obstet Gynecol 85: 1007-1010
24. Huizing M T, Keung ACF, Rosing H, van der Kuij V, ten Bokkel-Huinink W W, Mandjes I M, Dubbelman ARC, Pinedo H M and Beijnen J H (1993) Pharmacokinetics of paclitaxel and metabolism in a randomised comparative study in platinum-pretreated ovarian cancer patients. J Clin Oncol 11: 2127-2135
25. 2 as a 3-hour infusion. Clin Drug Invest 9: 344-353
26. Kearns C M, Belani C P, Erkmen K, Zuhowski M, Hiponia D, Engstrom C, Ramanathan R, Trenn M and Egorin M J (1995) Reduced platelet toxicity with combination carboplatin and paclitaxel: pharmacodynamic modulation of carboplatin associated thrombocytopenia. Proceedings of the International Symposium on Platinum and other Metal Compounds in Cancer Chemotherapy, Amsterdam. Abstract 070. Plenum Press: New York
27. Kohn E, Reed E, Link C, Christian M, Davis P and Sarosy G (1993) A pilot study of taxol, cisplatin, cyclophosphamide, and G-CSF in newly diagnosed stage III/IV ovarian cancer. Proc Am Soc Clin Oncol 12: 257 (814).
28. Kohn E C, Sarosy G, Bicher A, Link C, Christian M, Steinberg S M, Rothenberg M, Adamo D O, Davis P, Ognibene F P, Cunnion R E and Reed E (1994) Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. J Nat Cancer Inst 86: 18-24
29. 2 as first line chemotherapy (CT) in ovarian cancer (OC). Proc Am Soc Clin Oncol 14: 798
30. McGuire W P, Hoskin W J, Brady M F, Kucera P R, Look K Y, Partridge E E and Davidson M (1993) A Phase III trial comparing cisplatin/cytoxan (PC) and cisplatin/taxol (PT) in advanced ovarian cancer (AOC). Proc Am Soc Clin Oncol 12: 255 (808)
31. McGuire W P, Hoskins W J Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L and Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. New Engl J Med 334: 1-7
32. McGuire W P, Rowinsky E K, Rosenshein N B, Grumbine F C, Ettinger D S, Armstrong D K and Donehower R C (1989) Taxol (T): a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Inter Med 111: 273-279
33. Nabboltz J M, Gelmon K, Bontenbal M, Spielmann M, Clavel M, Seeber S, Conte P, Namer M, Bonneterre J, Fumoleau P, Sulkes A, Sauter C, Roche H, Calvert H, Kaufmann J, Chazard M, Diergarten K, Gallant G, Thompson M, Winograd B and Onetto N (1993) Randomized trial of Taxol in metastatic breast cancer: an interim analysis. Proc Am Soc Clin Oncol 12: 60 (42)
34. O'Brien J M, Wewers M D, Moore S A and Allen J N (1995) Taxol and colchicine increase LPS-induced Pro-IL-1b production, but do not increase IL-1b secretion. J Immunol 154: 4113-4222
35. Ozols R F, Kilpatrick D, O'Dwyer P, Hohnson S, Bookman M A, Walczak J, Rowinsky E and McGuire W P (1993) Phase I and pharmacokinetic study of paclitaxel (T) and carboplatin (C) in previously untreated patients (PTS) with advanced epithelial ovarian cancer (OC): a pilot study of the Gynaecologic Oncology Group. Proc Am Soc Clin Oncol 12: 259 (824)
36. Rowinsky E K, Chaudhry V, Forastiere A A, Sartoius S E, Ettinger D S, Grochow L B, Lubejko B G, Cornblath D R and Donehower R C (1993) Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony stimulating factor: neuromuscular toxicity is dose limiting. J Clin Oncol 11: 2010-2020
37. Rowinsky E K, Gilbert M R, McGuire W P, Noe D A, Grochow L B, Forastiere A A, Ettinger D S, Lubejko B G, Clark B, Sartorius S E, Cornblath D R, Hendricks C B and Donehower R C (1991) Sequences of taxol and cisplatin: a phase I and pharmacologic study. J Clin Oncol 9: 1692-1703
38. Sarosy G, Kohn E, Stone D A, Rothenberg M, Jacob J, Adamo D O, Ognibene F P, Cunnion R E and Reed E (1992) Phase I study of taxol and granulocyte colony stimulating factor in patients with refractory ovarian cancer. J Clin Oncol 10: 1165-1170
39. Thigpen T, Vance R, Puneky L and Khansur T (1994) Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials. Gynecol Oncol 55: S97-S107
40. Trimble E L, Adams J D, Vena D, Hawkins M J, Friedman M A, Fisherman J S, Christian M C, Canetta R, Onetto N, Hayn R and Arbuck S G (1993) Paclitaxel for platinum refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol 11: 2405-2410
41. Tuxen M K, Soletormow G and Dombernowsky P (1995) Tumour markers in the management of patients with ovarian cancer. Cancer Treat Rev 21: 215-245
42. Wild M D, Walle U K and Walle T (1995) Extensive and saturable accumulation of paclitaxel by the human platelet. Cancer Chemother Pharmacol 36: 41-44
43. Wiltshaw E, Evans B, Rustin G, Gilbey E, Baker J and Barker G (1986) A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma. J Clin Oncol 4: 772-729
44. Wiltshaw E, Subramarian S, Alexopoulos C and Barker GH (1979) Cancer of the ovary: a summary of experience with cis-dichlorodiamminoplatinum(II) at the Royal Marsden Hospital. Cancer Treat Reports 63: 1545-1548
45. Woods C M, Zhu J, McQueney P A, Bollag D and Lazarides E (1995) Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. Molecular Medicine 1: 506-526